{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:48:34Z","timestamp":1790171314999,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/annonc\/mdv622","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T02:06:34Z","timestamp":1451354794000},"page":"434-441","source":"Crossref","is-referenced-by-count":211,"title":["Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"K.A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Stallworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.S.","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Caudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.M.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.T.","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv622_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CMR.0b013e328352dbef","article-title":"Melanoma in the brain: biology and therapeutic options","volume":"22","author":"Gibney","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdv622_bb0015","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv622_bb0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0360-3016(01)02772-9","article-title":"Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery","volume":"52","author":"Yu","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdv622_bb0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.14694\/EdBook_AM.2013.33.399","article-title":"Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases","author":"Ramakrishna","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1093\/annonc\/mdv622_bb0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdv622_bb0040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv622_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv622_bb0060","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","article-title":"Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma","volume":"31","author":"Anker","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","article-title":"Vemurafenib and radiosensitization","volume":"149","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1093\/annonc\/mdv622_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","article-title":"Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports","volume":"190","author":"Schulze","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdv622_bb0075","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdv622_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","article-title":"Vemurafenib and radiation therapy in melanoma brain metastases","volume":"113","author":"Narayana","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdv622_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdv622_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdv622_bb0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdv622_bb0105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"key":"10.1093\/annonc\/mdv622_bb0110","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv622_bb0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv622_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdv622_bb0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2010.29.6053","article-title":"Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis","volume":"29","author":"Sun","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0135","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.seminoncol.2004.07.013","article-title":"Cognitive sequelae of brain radiation in adults","volume":"31","author":"Laack","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0140","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv622_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","article-title":"Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032","volume":"98","author":"Sambade","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0155","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cncr.20447","article-title":"Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity","volume":"101","author":"Radbill","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv622_bb0165","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2006.01.024","article-title":"Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy","volume":"65","author":"Gaudy-Marqueste","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdv622_bb0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article","volume":"114","author":"Liew","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdv622_bb0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/his.12537","article-title":"Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases","volume":"66","author":"Berghoff","year":"2015","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdv622_bb0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv622_bb0185","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv622_bb0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv622_bb0195","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv622_bb0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/3\/434\/6678656\/mdv622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:51:14Z","timestamp":1624693874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419356121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0923753419356121"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv622","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}